Erin N. Schuette

Erin N. Schuette

Auto-generated profile, based on publicly available information

Erin N. Schuette

Department of Cellular and Integrative Physiology, and CardiOmics Program, Center for Heart and Vascular Research, University of Nebraska Medical Center, Omaha, NE, 68198, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2025 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
SSSabarinath Peruvemba Subramanian
Sabarinath Peruvemba Subramanian
MWMelinda Wojtkiewicz
Melinda Wojtkiewicz
FYFang Yu
Fang Yu
CCChase Castro
Chase Castro
ESErin N. Schuette
Erin N. Schuette
RGRebekah Gundry
Rebekah Gundry
Coronavirus infectious disease of 2019 (COVID-19) can lead to cardiac complications, yet the molecular mechanisms driving these effects remain unclear. Protein glycosylation is crucial for viral replication, immune response, and organ function and has been found to change in the lungs and liver of patients with COVID-19. However, how COVID-19 impacts cardiac protein glycosylation has not been defined. Our study combined single nuclei transcriptomics, mass spectrometry (MS)-based glycomics, and lectin-based tissue imaging to investigate alterations in N-glycosylation in the human heart post-COVID-19. We identified significant expression differences in glycogenes involved in N-glycan biosynthesis and MS analysis revealed a reduction in high mannose and isomers of paucimannose structures post-infection, with changes in paucimannose directly correlating with COVID-19 independent of comorbidities. Our observations suggest that COVID-19 primes cardiac tissues to alter the glycome at all levels, namely, metabolism, nucleotide sugar transport, and glycosyltransferase activity. Given the role of N-glycosylation in cardiac function, this study provides a basis for understanding the molecular events leading to cardiac damage post-COVID-19 and informing future therapeutic strategies to treat cardiac complications resulting from coronavirus infections.